Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD74 | P04233 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 9/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CBX7 | O95931 | 6/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 6/20 | 0.43 |
| ▸ | CDYL2 | Q8N8U2 | 5/20 | 0.43 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539784 | 0.85 | CD74 (0.42) | CD74MIFIDO1KMT2APOLB | |
| SCHEMBL5252825 | 0.78 | CD74 (0.53) | CD74MIFIDO1KMT2ACBX7 | |
| SCHEMBL5287521 | 0.78 | MIF (0.53) | CD74MIFKMT2APOLB | |
| SCHEMBL30690128 | 0.78 | CD74 (0.53) | CD74MIFIDO1KMT2ACBX7 | |
| SCHEMBL5544720 | 0.78 | IDO1 (0.57) | IDO1KMT2A | |
| SCHEMBL13961602 | 0.74 | CD74 (0.64) | CD74MIFIDO1KMT2ACBX7 | |
| SCHEMBL14615589 | 0.74 | CD74 (0.49) | CD74MIFIDO1KMT2ACBX7 | |
| SCHEMBL2149143 | 0.73 | CD74 (0.62) | CD74MIFIDO1KMT2ACBX7 | |
| SCHEMBL3543457 | 0.72 | TSHR (0.57) | MIFIDO1 | |
| SCHEMBL18805702 | 0.69 | MIF (1.00) | CD74MIFIDO1KMT2ACBX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CD74 2071/4885MIF 1824/4885IDO1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.